|Year : 2019 | Volume
| Issue : 10 | Page : 856-859
Thrombosis incidence after recombinant active factor VII administration in paediatric cardiac surgery
Keitaro Tachi1, Shinji Takahashi1, Maiko Ishigaki1, Shin Nakayama1, Soichiro Yamashita1, Yuji Hiramatsu2, Makoto Tanaka1
1 Department of Anesthesiology, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
2 Department of Cardiac Surgery, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
|Date of Submission||15-Mar-2019|
|Date of Decision||13-Jun-2019|
|Date of Acceptance||15-Jul-2019|
|Date of Web Publication||10-Oct-2019|
Dr. Shinji Takahashi
Department of Anesthesiology, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Tachi K, Takahashi S, Ishigaki M, Nakayama S, Yamashita S, Hiramatsu Y, Tanaka M. Thrombosis incidence after recombinant active factor VII administration in paediatric cardiac surgery. Indian J Anaesth 2019;63:856-9
|How to cite this URL:|
Tachi K, Takahashi S, Ishigaki M, Nakayama S, Yamashita S, Hiramatsu Y, Tanaka M. Thrombosis incidence after recombinant active factor VII administration in paediatric cardiac surgery. Indian J Anaesth [serial online] 2019 [cited 2020 Feb 17];63:856-9. Available from: http://www.ijaweb.org/text.asp?2019/63/10/856/268705
| Introduction|| |
Bleeding following complex congenital cardiac surgery under cardiopulmonary bypass (CPB) is a serious problem. It results from long durations of CPB, hypothermia and the complex anastomoses involved in these procedures., The outcomes of intraoperative administration of recombinant activated factor VII (rFVIIa) during paediatric cardiac surgery have not been extensively studied. We aimed to review paediatric cardiac operations involving rFVIIa administration performed at our hospital and compare the incidence of postoperative thrombosis with or without rFVIIa.
| Methods|| |
This retrospective observational study was approved by our institutional ethics committee. We reviewed the electronic anaesthesia records (FortecORSYS®; Philips Japan Ltd, Tokyo, Japan) of patients >6 years who underwent open heart surgery and received rFVIIa (NovoSeven®; Novo Nordisk, Bagsbaerd, Denmark) between April 2011 and March 2015 (treated group) at our institution. We also identified patients who underwent the same procedure without rFVIIa administration (untreated group).
The following data were extracted from the anaesthetic and/or medical records: (1) preoperative data: age, weight, past sternotomy, results of coagulation tests including prothrombin time (PT), activated partial thromboplastin time (APTT) and platelet count; (2) intraoperative data: infusion volume, blood transfusion volume, operation time, anaesthesia time, CPB time and rFVIIa dosage and (3) postoperative data: results of coagulation tests, postoperative transfusion volume and drainage volume from the chest drain over 24 h after the surgery.
For CPB, anticoagulation was achieved by heparin administration to attain an activated coagulation time of 400 s. At the end of CPB, heparin was neutralised with protamine. rFVIIa was administered when haemorrhage persisted 2 h after protamine administration despite surgical haemostatic procedures and coagulation management by transfusion. The initial dose was 90 μg/kg, and if haemostasis was not achieved within 2 h, the same dose was repeated. Haemostasis was evaluated based on visual inspection of bleeding in the surgical field by the surgeon. Postoperative thrombotic complications were routinely evaluated by clinical examination, transthoracic echocardiography on postoperative day 1 and computed tomography after extubation. Early postoperative computed tomography of the chest was only performed in a patient with suspected pulmonary embolism on transthoracic echocardiography. Thrombosis was diagnosed based on clinical symptoms or imaging findings. The primary outcome was the incidence of thrombosis, whereas the secondary outcomes were re-thoracotomy for bleeding, duration of postoperative intensive care unit (ICU) and hospital stays, and 30-day mortality rates. Statistical analysis was performed using SPSS Statistics version 23® (IBM Japan, Ltd., Tokyo, Japan). Patient characteristics and perioperative data were compared using Mann–Whitney U-test and χ2 test using cross tabulation. A P value <0.05 was considered statistically significant. The values are expressed as mean ± standard deviation.
| Results|| |
Preoperative examination showed significantly longer PT (P = 0.002) and APTT (P = 0.048) in the treated group [Table 1]. The treated group had a lower platelet count at the end of CPB (P = 0.030), required a longer time to achieve haemostasis after CPB (P < 0.001) and received larger volumes of intraoperative FFP (P < 0.001) and platelet concentrate [P < 0.001; [Table 2] transfusions. Of the 275 patients who underwent surgery under CPB, 12 (4.4%) received rFVIIa and 17 did not. The postoperative thrombosis rates in the treated and untreated groups were 1/12 (8.3%) and 4/17 (23.5%), respectively.
|Table 1: Preoperative characteristics and comparison between recombinant activated factor VII-treated and -untreated groups|
Click here to view
|Table 2: Comparison of intraoperative data and postoperative outcomes between recombinant activated factor VII-treated and -untreated groups|
Click here to view
One patient in the treated group showed cerebral infarction on imaging studies without symptoms. The patients with thrombosis in the untreated group included one with pulmonary embolism with SpO2 reduction, one with pulmonary embolism on transthoracic echocardiography and computed tomography without clinical symptoms and two with cerebral infarction on imaging with no clinical symptoms. rFVIIa administration did not increase the postoperative thrombosis rate (P = 0.168), duration of postoperative ICU (P = 0.913) and hospital stays (P = 0.211), re-sternotomy rate (P = 0.286) or the 30-day mortality rate (P = 0.348) [Table 2]. The coagulation activity in the treated group was significantly higher in terms of PT (P < 0.001) and APTT (P = 0.012) at ICU admission. There was no significant difference in blood transfusion volume in the ICU and during postoperative extracorporeal membrane oxygenation (ECMO) support [Table 2]. There were no cases of thrombosis that required the introduction of ECMO or resuscitation for cardiac arrest.
| Discussion|| |
We investigated the outcomes of rFVIIa administration in paediatric patients undergoing cardiac surgeries. Generally, rFVIIa serves as a rescue therapy for bleeding that cannot be controlled with standard haemostatic therapy. A great concern is whether off-label rFVIIa administration can increase the incidence of perioperative arterial or venous thrombosis.,,, The increased risk of thrombosis after rFVIIa administration during paediatric cardiac surgery has been reported previously., However, the high rates of ECMO use in the rFVIIa-treated groups may be related to the incidence of thrombosis.,, The difference between our study and previous studies is the reduction in serious symptoms due to thrombosis and the low rates of postoperative ECMO. ECMO is used after poor surgical reconstruction or for attenuated cardiac function during surgery. Slowing or pooling of blood may promote thrombogenesis. In this study, administration of rFVIIa might not have increased the risk of thrombosis because the postoperative rate of ECMO use was equivalent in both groups. Our study population may thus have been at a lower risk of thrombosis.
Cardiopulmonary reserve is limited in children, especially after CPB, and they cannot tolerate volume overload. Once factor VII levels fall secondary to acute massive bleeding, they are difficult to correct using general transfusion therapy. The advantages of rFVIIa over blood transfusion include more effective restoration of blood factor VII level, less probability of infection, smaller volume loads, and rapid preparation and administration.
There are several limitations to this study. First, this was a retrospective study conducted at a single facility. Propensity score matching could not be performed due to the small sample size. In our country, rFVIIa is used in an off-label manner and is extremely expensive. Therefore, it is difficult to increase the number of cases performed using it. Second, there is a possibility that asymptomatic thromboses were missed, despite evaluation using CT and transthoracic echocardiography.
| Conclusion|| |
rFVIIa administration during paediatric cardiac surgery did not increase the incidence of postoperative thrombosis or the 30-day mortality rate.
The authors would like to thank Editage (www.editage.jp) for English language editing.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
Keitaro Tachi acquired the data and prepared the article. Shinji Takahashi designed the study and analysed the data. Maiko Ishigaki acquired the data and reviewed the article. Shin Nakayama acquired the data and reviewed the article. Soichiro Yamashita acquired the data and reviewed the article. Yuji Hiramatsu reviewed the article. Makoto Tanaka reviewed the article. The article has been read and approved by all the authors.
| References|| |
Williams GD, Bratton SL, Ramamoorthy C. Factors associated with blood loss and blood product transfusions: A multivariate analysis in children after open-heart surgery. Anesth Analg 1999;89:57-64.
Guzzetta NA, Allen NN, Wilson EC, Foster GS, Ehrlich AC, Miller BE. Excessive postoperative bleeding and outcomes in neonates undergoing cardiopulmonary bypass. Anesth Analg 2015;120:405-10.
Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N
Engl J Med 2010;363:1791-800.
O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293-8.
Downey L, Brown ML, Faraoni D, Zurakowski D, DiNardo JA. Recombinant factor VIIa is associated with increased thrombotic complications in pediatric cardiac surgery patients. Anesth Analg 2017;124:1431-6.
McQuilten ZK, Barnes C, Zatta A, Phillips LE, Haemostasis Registry Steering Committee. Off-label use of recombinant factor VIIa in pediatric patients. Pediatrics 2012;129:e1533-40.
Veldman A, Neuhaeuser C, Akintuerk H, Thul J, Gehron J, Schranz D, et al
. rFVIIa in the treatment of persistent hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease. Paediatr Anaesth 2007;17:1176-81.
Wittenstein B, Ng C, Ravn H, Goldman A. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med 2005;6:473-6.
Bolliger D, Görlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology 2010;113:1205-19.
[Table 1], [Table 2]